Esther Mc van Leijsen1, Mayra I Bergkamp1, Ingeborg Wm van Uden1, Sjacky Cooijmans1, Mohsen Ghafoorian2,3, Helena M van der Holst4, David G Norris5,6, Roy Pc Kessels7,8, Bram Platel2, Anil M Tuladhar1, Frank-Erik de Leeuw1. 1. Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Donders Center for Medical Neuroscience, Radboudumc, Nijmegen, The Netherlands. 2. Department of Radiology and Nuclear Medicine, Diagnostic Image Analysis Group, Radboudumc, Nijmegen, The Netherlands. 3. Institute for Computing and Information Sciences, Radboud University, Nijmegen, The Netherlands. 4. Department of Neurology, Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, The Netherlands. 5. Donders Institute for Brain, Cognition and Behaviour, Centre for Cognitive Neuroimaging, Radboud University, Nijmegen, The Netherlands. 6. Erwin L. Hahn Institute for Magnetic Resonance Imaging, University of Duisburg-Essen, Essen, Germany. 7. Department of Medical Psychology, Radboud Alzheimer Centre, Radboudumc, Nijmegen, The Netherlands. 8. Radboud University, Donders Institute for Brain, Cognition and Behaviour, Centre for Cognition, Nijmegen, The Netherlands.
Abstract
INTRODUCTION: Recent studies have shown that neuroimaging markers of cerebral small vessel disease can also regress over time. We investigated the cognitive consequences of regression of small vessel disease markers. PATIENTS AND METHODS: Two hundred and seventy-six participants of the RUNDMC study underwent neuroimaging and cognitive assessments at three time-points over 8.7 years. We semi-automatically assessed white matter hyperintensities volumes and manually rated lacunes and microbleeds. We analysed differences in cognitive decline and accompanying brain atrophy between participants with regression, progression and stable small vessel disease by analysis of variance. RESULTS: Fifty-six participants (20.3%) showed regression of small vessel disease markers: 31 (11.2%) white matter hyperintensities regression, 10 (3.6%) vanishing lacunes and 27 (9.8%) vanishing microbleeds. Participants with regression showed a decline in overall cognition, memory, psychomotor speed and executive function similar to stable small vessel disease. Participants with small vessel disease progression showed more cognitive decline compared with stable small vessel disease (p < 0.001 for cognitive index and memory; p < 0.01 for executive function), although significance disappeared after adjusting for age and sex. Loss of total brain, gray matter and white matter volume did not differ between participants with small vessel disease regression and stable small vessel disease, while participants with small vessel disease progression showed more volume loss of total brain and gray matter compared to those with stable small vessel disease (p < 0.05), although significance disappeared after adjustments. DISCUSSION: Regression of small vessel disease markers was associated with similar cognitive decline compared to stable small vessel disease and did not accompany brain atrophy, suggesting that small vessel disease regression follows a relatively benign clinical course. Future studies are required to validate these findings and to assess the role of vascular risk factor control on small vessel disease regression and possible recovery of clinical symptoms. CONCLUSION: Our findings of comparable cognitive decline between participants with regression and stable small vessel disease might suggest that small vessel disease regression has a relative benign cognitive outcome.
INTRODUCTION: Recent studies have shown that neuroimaging markers of cerebral small vessel disease can also regress over time. We investigated the cognitive consequences of regression of small vessel disease markers. PATIENTS AND METHODS: Two hundred and seventy-six participants of the RUNDMC study underwent neuroimaging and cognitive assessments at three time-points over 8.7 years. We semi-automatically assessed white matter hyperintensities volumes and manually rated lacunes and microbleeds. We analysed differences in cognitive decline and accompanying brain atrophy between participants with regression, progression and stable small vessel disease by analysis of variance. RESULTS: Fifty-six participants (20.3%) showed regression of small vessel disease markers: 31 (11.2%) white matter hyperintensities regression, 10 (3.6%) vanishing lacunes and 27 (9.8%) vanishing microbleeds. Participants with regression showed a decline in overall cognition, memory, psychomotor speed and executive function similar to stable small vessel disease. Participants with small vessel disease progression showed more cognitive decline compared with stable small vessel disease (p < 0.001 for cognitive index and memory; p < 0.01 for executive function), although significance disappeared after adjusting for age and sex. Loss of total brain, gray matter and white matter volume did not differ between participants with small vessel disease regression and stable small vessel disease, while participants with small vessel disease progression showed more volume loss of total brain and gray matter compared to those with stable small vessel disease (p < 0.05), although significance disappeared after adjustments. DISCUSSION: Regression of small vessel disease markers was associated with similar cognitive decline compared to stable small vessel disease and did not accompany brain atrophy, suggesting that small vessel disease regression follows a relatively benign clinical course. Future studies are required to validate these findings and to assess the role of vascular risk factor control on small vessel disease regression and possible recovery of clinical symptoms. CONCLUSION: Our findings of comparable cognitive decline between participants with regression and stable small vessel disease might suggest that small vessel disease regression has a relative benign cognitive outcome.
Entities:
Keywords:
Cerebral small vessel disease; cognitive decline; magnetic resonance imaging
Authors: Joanna M Wardlaw; Francesca M Chappell; Maria Del Carmen Valdés Hernández; Stephen D J Makin; Julie Staals; Kirsten Shuler; Michael J Thrippleton; Paul A Armitage; Susana Muñoz-Maniega; Anna K Heye; Eleni Sakka; Martin S Dennis Journal: Neurology Date: 2017-08-09 Impact factor: 9.910
Authors: Anouk Gw van Norden; Karlijn F de Laat; Rob Ar Gons; Inge Wm van Uden; Ewoud J van Dijk; Lucas Jb van Oudheusden; Rianne Aj Esselink; Bastiaan R Bloem; Baziel Gm van Engelen; Machiel J Zwarts; Indira Tendolkar; Marcel G Olde-Rikkert; Maureen J van der Vlugt; Marcel P Zwiers; David G Norris; Frank-Erik de Leeuw Journal: BMC Neurol Date: 2011-02-28 Impact factor: 2.474
Authors: Esther M C van Leijsen; Ingeborg W M van Uden; Mohsen Ghafoorian; Mayra I Bergkamp; Valerie Lohner; Eline C M Kooijmans; Helena M van der Holst; Anil M Tuladhar; David G Norris; Ewoud J van Dijk; Loes C A Rutten-Jacobs; Bram Platel; Catharina J M Klijn; Frank-Erik de Leeuw Journal: Neurology Date: 2017-09-06 Impact factor: 9.910
Authors: Joanna M Wardlaw; Eric E Smith; Geert J Biessels; Charlotte Cordonnier; Franz Fazekas; Richard Frayne; Richard I Lindley; John T O'Brien; Frederik Barkhof; Oscar R Benavente; Sandra E Black; Carol Brayne; Monique Breteler; Hugues Chabriat; Charles Decarli; Frank-Erik de Leeuw; Fergus Doubal; Marco Duering; Nick C Fox; Steven Greenberg; Vladimir Hachinski; Ingo Kilimann; Vincent Mok; Robert van Oostenbrugge; Leonardo Pantoni; Oliver Speck; Blossom C M Stephan; Stefan Teipel; Anand Viswanathan; David Werring; Christopher Chen; Colin Smith; Mark van Buchem; Bo Norrving; Philip B Gorelick; Martin Dichgans Journal: Lancet Neurol Date: 2013-08 Impact factor: 44.182
Authors: Joel Ramirez; Alicia A McNeely; Courtney Berezuk; Fuqiang Gao; Sandra E Black Journal: Front Aging Neurosci Date: 2016-03-24 Impact factor: 5.750
Authors: I W M van Uden; H M van der Holst; P Schaapsmeerders; A M Tuladhar; A G W van Norden; K F de Laat; D G Norris; J A H R Claassen; E J van Dijk; E Richard; R P C Kessels; F-E de Leeuw Journal: BBA Clin Date: 2015-10-26
Authors: Selma Lugtmeijer; Linda Geerligs; Frank Erik de Leeuw; Edward H F de Haan; Roy P C Kessels Journal: Brain Struct Funct Date: 2021-04-29 Impact factor: 3.270
Authors: Ahmed A Bahrani; Charles D Smith; Justin M Barber; Omar M Al-Janabi; David K Powell; Anders H Andersen; Brandon D Ramey; Erin L Abner; Larry B Goldstein; Zachary Winder; Brian T Gold; Linda Van Eldik; Donna M Wilcock; Gregory A Jicha Journal: J Neurosci Methods Date: 2021-06-24 Impact factor: 2.987
Authors: Muhammad Febrian Rachmadi; Maria Del C Valdés-Hernández; Stephen Makin; Joanna Wardlaw; Taku Komura Journal: Med Image Anal Date: 2020-04-26 Impact factor: 8.545
Authors: Omar M Al-Janabi; Christopher E Bauer; Larry B Goldstein; Richard R Murphy; Ahmed A Bahrani; Charles D Smith; Donna M Wilcock; Brian T Gold; Gregory A Jicha Journal: Brain Sci Date: 2019-07-19